Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2922635 | 0.83 | PDGFRB (0.56) | CYP1A2CYP3A4CLK4CYP2C19USP2 | |
| SCHEMBL3367543 | 0.82 | SLC6A3 (0.39) | CYP2C19HSD17B10ALDH1A1CYP2D6HPGD | |
| SCHEMBL3569637 | 0.80 | MAPK7 (0.38) | KIT | |
| SCHEMBL3364384 | 0.79 | CYP1A2 (0.44) | CYP1A2CYP3A4CLK4CYP2C19USP2 | |
| SCHEMBL3364381 | 0.78 | ALDH1A1 (0.38) | CYP1A2CYP3A4CYP2C19USP2HSD17B10 | |
| SCHEMBL4969429 | 0.74 | MAPK7 (0.48) | — | |
| SCHEMBL3366836 | 0.72 | PDGFRB (0.58) | CYP1A2CYP3A4CLK4CYP2C19USP2 | |
| SCHEMBL2921599 | 0.70 | HTT (0.58) | CYP1A2CYP3A4CLK4CYP2C19USP2 | |
| SCHEMBL3364377 | 0.70 | HRH3 (0.53) | CYP1A2CYP3A4CLK4CYP2C19USP2 | |
| SCHEMBL27469934 | 0.69 | PRMT5 (0.66) | HTTPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-6956039-B2 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1309569-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016362-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | WNK2, CDK5, WNK1 | CYP1A2 4614/4885CYP3A4 4711/4885CLK4 1211/4885 |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | WNK2, CDK5, WNK1 | CYP1A2 4314/4885CYP3A4 4488/4885CLK4 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.